PainReform Provides Business Update for the Third Quarter of 2021
Reports continued progress towards commencing Phase 3 clinical trials Announces Selection of Pharmaceutics International, Inc.as U.S. Manufacturer of PRF-110 for Upcoming Phase 3 Trial Tel Aviv, Israel – November 16, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a […]
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
Tel Aviv, Israel – October 14, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 […]
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
PainReform Provides Business Update for the Second Quarter of 2021
Tel Aviv, Israel – August 16, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the second quarter ended June 30, 2021. “We are continuing the steady progress towards commencement of our Phase 3 clinical trials […]
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
PainReform Provides Business Update for the First Quarter of 2021
HERZLIYA, Israel – May 13, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2021. The Company also announces it has finalized the protocol for its Phase 3 clinical trials […]
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
HERZLIYA, Israel – March 17, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. The Company also reported it has filed its annual report on Form 20-F. Significant events and achievements during the fourth quarter […]
PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
HERZLIYA, Israel – March 11, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited to present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim […]
PainReform Announces $6.0 Million Private Placement
HERZLIYA, Israel – March 8, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics,today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through the private placement of 1,304,346 ordinary shares and […]
PainReform to Present at the H.C. Wainwright Bioconnect 2021 Conference
HERZLIYA, Israel – January 6, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. A webcast of PainReform’s presentation will be […]
